280 related articles for article (PubMed ID: 16522575)
1. Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom.
Morgan SG; McMahon M; Mitton C; Roughead E; Kirk R; Kanavos P; Menon D
Health Aff (Millwood); 2006; 25(2):337-47. PubMed ID: 16522575
[TBL] [Abstract][Full Text] [Related]
2. Centralized drug review processes: are they fair?
Mitton CR; McMahon M; Morgan S; Gibson J
Soc Sci Med; 2006 Jul; 63(1):200-11. PubMed ID: 16427728
[TBL] [Abstract][Full Text] [Related]
3. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
[TBL] [Abstract][Full Text] [Related]
4. Drugs down under.
Wonder MJ; Wyber D
Health Aff (Millwood); 2006; 25(4):1185; author reply 1185-6. PubMed ID: 16835205
[No Abstract] [Full Text] [Related]
5. Centralising drug review to improve coverage decisions: economic lessons from (and for) Canada.
Morgan S; McMahon M; Mitton C
Appl Health Econ Health Policy; 2006; 5(2):67-73. PubMed ID: 16872248
[TBL] [Abstract][Full Text] [Related]
6. A role for two-stage pharmacoeconomic appraisal? Is there a role for interim approval of a drug for reimbursement based on modelling studies with subsequent full approval using phase III data?
Hill S; Freemantle N
Pharmacoeconomics; 2003; 21(11):761-7. PubMed ID: 12859218
[TBL] [Abstract][Full Text] [Related]
7. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
8. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998.
Rawson NS
CMAJ; 2000 Feb; 162(4):501-4. PubMed ID: 10701383
[TBL] [Abstract][Full Text] [Related]
9. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
10. The subsidy of pharmaceuticals in Australia: processes and challenges.
Sansom L
Aust Health Rev; 2004 Nov; 28(2):194-205. PubMed ID: 15527399
[TBL] [Abstract][Full Text] [Related]
11. Human resources for the approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States.
Rawson NS
Can J Clin Pharmacol; 2002; 9(2):73-8. PubMed ID: 12172587
[TBL] [Abstract][Full Text] [Related]
12. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
Rocchi A; Menon D; Verma S; Miller E
Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
[TBL] [Abstract][Full Text] [Related]
13. Priority-setting processes for medicines: the United Kingdom, Australia and New Zealand.
Manning J
J Law Med; 2011 Mar; 18(3):439-52. PubMed ID: 21528732
[TBL] [Abstract][Full Text] [Related]
14. [Authorization and reimbursement of orphan drugs in an international comparison].
Roll K; Stargardt T; Schreyögg J
Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
[TBL] [Abstract][Full Text] [Related]
15. Comparing the Approval and Coverage Decisions of New Oncology Drugs in the United States and Other Selected Countries.
Zhang Y; Hueser HC; Hernandez I
J Manag Care Spec Pharm; 2017 Feb; 23(2):247-254. PubMed ID: 28125371
[TBL] [Abstract][Full Text] [Related]
16. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
Lopert R
Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
[TBL] [Abstract][Full Text] [Related]
17. Medicine reimbursement recommendations in Canada, Australia, and Scotland.
Lexchin J; Mintzes B
Am J Manag Care; 2008 Sep; 14(9):581-8. PubMed ID: 18778173
[TBL] [Abstract][Full Text] [Related]
18. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand.
Raftery JP
Med J Aust; 2008 Jan; 188(1):26-8. PubMed ID: 18205559
[TBL] [Abstract][Full Text] [Related]
19. Four countries shed light on drug-review policies.
Young D
Am J Health Syst Pharm; 2005 Jun; 62(11):1122-3, 1130. PubMed ID: 15914872
[No Abstract] [Full Text] [Related]
20. Coverage with evidence development for pharmaceuticals: a policy in evolution?
Lexchin J
Int J Health Serv; 2011; 41(2):337-54. PubMed ID: 21563627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
